B019

BIOLOGICAL2 trials

Sponsors

Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.

Conditions

Relapsed or Refractory B Cell Non Hodgkin LymphomaRelapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Phase 1

A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.

RecruitingNCT06927466

Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Start: 2024-09-19End: 2028-06-30Target: 33Updated: 2026-08-17

A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.

Not yet recruitingNCT06970496

Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.Relapsed or Refractory B Cell Non Hodgkin Lymphoma

Start: 2026-08-31End: 2027-12-31Target: 48Updated: 2026-08-14